Opyt primeneniya etanertsepta pri rannem yuvenil'nom ankiloziruyushchem spondiloartrite


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The article presents a case of debut juvenile ankylosing spondylitis, characterized by rapid development of asymmetric poliarticular syndrome, sacroiliitis, disability of patient, and low quality of life of the child and his family. Suppression of the activity of the pathological process was achieved due to the successful application of soluble receptors for tumor necrosis factor α, etanercept. The function of affected joints was completely recovered, and quality of life was significantly improved. Inactive phase of the disease during treatment with etanercept was recorded after 4 weeks, remission - at 7th month of treatment.

Толық мәтін

Рұқсат жабық

Әдебиет тізімі

  1. Cassidy JT, Petty RE Laxer RM, et al. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2010:794.
  2. Никишина И.П. Диагностика ювенильных спондилоартритов: классификационньй и нозологический подходы // Consilium medi-cum 2006. Т. 8. № 2. С. 20-3.
  3. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J Rheumatol 2002;29:1520-30.
  4. Бочкова А.Г. Серонегативнье спондилоартриты лечение анкилозирующего спондилита // Consilium Medicum 2006. Т. 8. № 2.
  5. Kalden JR. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res 2002;4(2):534-40.
  6. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999;26 (57):16-21.
  7. Reed MR, Taylor AL. Tumor necrosis factor inhibitors in ankylosing spondylitis. Intern Med J 2008;38(10):781-89.
  8. Griffoul I, Giraudeau B, Mulleman D, et al. Infliximab for treating axial spondylarthropathy in everyday practice. Joint Bone Spine 2009;76(1):39-43.
  9. Козлова А.Л., Алексеева Е.И., Валиева С.И. Эффективность инфликсимаба у больных ювенильным анкилозирующим спондилоартритом // Вопросы современной педиатрии 2009. Т.8. № 2. С. 20-6.
  10. Алексеева Е.И., Козлова А.Л., Валиева С.И. Новые возможности лечения ювенильного анкилозирующего спондилоартрита // Вопрось современной педиатрии 2010. Т. 9. № 2. С. 23-31.
  11. Алексеева Е.И., Валиева С.И, Денисова Р.В.Перспективы применения растворимых рецепторов к ФНО-α в терапии ювенильных артритов // Вопрось современной педиатрии 2008. Т. 7. № 5. С. 51-7.
  12. Moreland LW, Schiff MH, Baumgarthner SW, et al. Etanercept therapy in rheumatoid arthritis. Ann Int Med 1999;130:478-86.
  13. Moreland LW, Scott MD, Baumgarther W, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-47.
  14. Twilt M, Ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 2008;68(5):635-41.
  15. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 2008;68(4):519-25.
  16. Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26(4):688-92.
  17. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58(5):1496-504.
  18. Palazzi C, D'Angelo S, Cantini F, et al. Etanercept in spondyloarthropathies. Part I: current evidence of efficacy. Clin Exp Rheumatol 2011;29(5):858-64.
  19. Navarro-Sarabia F, Fernandez-Sueiro JL, Torre-Alonso JC, Gratacos J, et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford) 2011;50(10): 1828-37.
  20. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011;63(6):1543-51.
  21. Dougados M, Braun J, Szanto S, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 2011;70(5):799-804.
  22. Huang F, Zhang J, Huang JL, et al. A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanerceptin treatment of ankylosing spondylitis. Article in Chinese Zhonghua. Nei Ke Za Zhi 2010;49(9): 741-45.
  23. Martin-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28(2):238-45.
  24. Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009 36(6):1256-64.
  25. Horneff G, Schmeling H, Moebius D, et al. Efficacy of etanercept in active refractory juvenile spondylarthropathy: prospective open study of 40 patients [abstract]. Arthritis Rheum 2004;50(Suppl. 9):S91.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2013

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>